QTTB
Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.79
+3.59%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +209.0%
- EBIT
- +139.2%
- EPS
- +164.9%
- Free cash flow
- +63.4%
- Operating cash flow
- +63.3%
Forward estimates
Based on analyst estimates
- Revenue
- -99.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +100.7%
- EBITDA
- +170.4%
- EBIT
- +125.6%
- Net income
- +162.5%
- EPS
- +147.3%
- Free cash flow
- +50.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026